The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features a real-time scorecard of the Q1 earnings season and freshly updated research reports on ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a diabetes treatment since 2019. It's an orally available version of semaglutide, ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, Wegovy, Mounjaro and Zepbound, a clinical trial shows.

Eli Lilly’s latest innovation, orforglipron, has emerged as a formidable contender in the weight-loss medication arena. The pill has demonstrated comparable results to Ozempic, a leading injectable ...

Steve brings deep experience in strategic transactions to Werewolf at this critical time,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. “Werewolf is ...

The company posted revenue of $109.6 billion and adjusted earnings of $7.20 per share, compared to the consensus estimates of ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks and ...

I n an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top executives met, like they had dozens of times before, to hear the ...